全球氨基糖苷类药物市场 - 2023-2030年

市场概况

全球氨基糖苷类药物市场在2022年达到16.364亿美元，预计到2030年将出现有利可图的增长，达到22.022亿美元。在预测期内（2023-2030年），全球氨基糖苷类药物市场预计将呈现3.8%的复合增长率。

全球氨基糖苷类药物市场是制药业中一个蓬勃发展的领域，主要是治疗严重的细菌感染。氨基糖苷类药物是重要的抗生素，在医院、诊所和研究实验室被广泛利用。最近的市场趋势显示，对组合药物的需求增加，以及对开发新配方的明显重视。全球氨基糖苷类药物市场的重要发展包括研发倡议、监管部门的批准，以及在兽医学中的应用不断增加。

细菌感染日益普遍，老龄人口不断增加，以及抗生素的大量使用是推动全球氨基糖苷类药物市场的因素。老年人口不断增加，对氨基糖苷类药物的需求也在增加。根据世界卫生组织2022年的预测，全球60岁及以上的人口预计将急剧增长。到2030年，全世界每六个人中就有一个是60岁或以上的人，这个年龄组的人口估计将达到14亿，而2020年是10亿。

市场动态

结核病发病率的上升正在推动全球氨基糖苷类药物市场的增长。

结核病发病率的上升是推动全球氨基糖苷类药物市场大幅上升的主要因素之一。像氨基糖苷类的强效抗生素对于有效治疗结核病这种严重的细菌性疾病是必要的。由于结核病发病率的上升，尤其是在发展中国家，对氨基糖苷类药物的需求正在增长。

例如，根据美国疾病控制和预防中心2023年的报告，在2022年，美国有8300个报告的结核病（TB）病例，导致每10万人中有2.5个病例。这比2021年报告的7,874个病例有小幅上升。2022年，结核病的发病率保持在每10万人2.5例。

兽医学中对氨基糖苷的需求不断增长，推动了全球氨基糖苷市场的增长。

氨基糖苷类药物在兽医学中的应用不断扩大，为市场参与者提供了一个有利可图的机会。在牲畜、伴侣动物和水产养殖中，氨基糖苷类药物通常被用来治疗细菌感染。这些氨基糖苷类药物在家禽和猪业中以饲料和水的形式施用。

例如，支原体和大肠杆菌是导致家禽呼吸道感染的最常见原因，需要用氨基糖苷类药物治疗。动物可以用氨基糖苷类药物治疗大肠杆菌、变形杆菌、假单胞菌、沙门氏菌、志贺氏菌、沙雷特氏菌和肠杆菌等细菌感染。由于这些原因，兽药在细菌感染中的使用将在预测期内推动全球氨基糖苷类药物市场的发展。

耐药性的发展阻碍了全球氨基糖苷类药物市场的增长。

抗生素耐药性是指细菌能够耐受抗生素的作用，使其在治疗细菌感染中失去作用。氨基糖苷类药物的长期和不适当使用导致了对这些抗生素有抗药性的细菌菌株的发展，降低了它们的效率。

例如，耐甲氧西林金黄色葡萄球菌（MRSA）和产生长谱β-内酰胺酶（ESBL）的细菌正在对氨基糖苷类药物产生耐药性。感染患者对氨基糖苷类药物的耐药率、表型和机制都有报道。抗生素耐药细菌，如MRSA和产ESBL的细菌，正在成为一个不断上升的公共卫生威胁。

COVID-19的影响分析

COVID-19的爆发对全球氨基糖苷类药物行业产生了实质性影响。这场大流行扰乱了全球供应链，减少了包括氨基糖苷类药物行业在内的各种行业对商品和服务的需求。COVID-19对氨基糖苷类药物市场最重要的影响之一是供应链的中断，这导致了氨基糖苷类抗生素产量的下降。

这场大流行也增加了抗生素的使用，因为个人越来越关注自己的健康，并服用足够的处方以避免感染和延长住院时间。然而，氨基糖苷类药物可能在抗击COVID-19方面有特别的好处。根据国家医学图书馆2021年发表的一篇论文，氨基糖苷类有可能成为SARS-CoV-2的抗病毒药物。在体外，氨基糖苷类药物hygromycin B（hygB）和新霉素证明了对小鼠肝炎病毒（MHV）的抑制。还有人发现hygB对牛和猫的冠状病毒有活性。

俄罗斯-乌克兰冲突分析

俄罗斯和乌克兰之间的冲突预计将对全球氨基糖苷市场产生实质性影响。因为战区的传染病发病率，导致了价格上涨，供应链中断，以及对氨基糖苷的需求增加。据预测，这些因素将减少市场需求，提高价格，并扰乱供应链，使病人难以获得基本的氨基糖苷类药物。

此外，冲突的间接影响，如较低的经济增长和较低的医疗服务需求，可能导致市场的悲观看法。虽然冲突的全部影响程度尚不清楚，但很明显，全球氨基糖苷类药物行业将受到严重的影响。

目录

第一章：方法和范围

• 研究方法
• 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

• 按产品类型简述
• 按给药途径分析
• 按应用分类
• 按地区分类

第四章：动态变化

• 影响因素
  • 驱动因素
    • 结核病发病率的上升推动了全球氨基糖苷市场的增长。
    • 氨基糖苷作为兽药的需求不断增长，推动了全球氨基糖苷市场的增长。
  • 限制因素
    • 耐药性的发展阻碍了全球氨基糖苷市场的增长。
  • 机会
  • 影响分析

第五章：行业分析

• 波特五力分析
• 供应链分析
• 未满足的需求
• 监管分析

第六章：COVID-19分析

• 对COVID-19的分析
  • COVID-19之前的情况
  • COVID-19期间的情况
  • COVID-19之后的情况
• 在COVID-19期间的定价动态
• 需求-供应谱系
• 大流行期间与市场有关的政府倡议
• 制造商的战略倡议
• 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：按产品类型

• 新霉素
• 妥布霉素
• 庆大霉素
• 阿米卡星
• 副霉素
• 链霉素
• 卡那霉素
• 其他

第九章：按给药途径分类

• 注射剂
• 饲料
• 乳房内
• 外用
• 口服

第十章：按应用分类

• 兽医
• 皮肤感染
• 呼吸系统疾病
• 尿毒症和盆腔疾病
• 其他疾病

第十一章：按地区划分

• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 南美其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
• 中东和非洲

第十二章 ：竞争格局

• 竞争格局
• 产品标杆
• 公司份额分析
• 主要发展和战略

第十三章 ：公司简介

• Pfizer Inc.
  • 公司概述
  • 产品组合和描述
  • 财务概况
  • 主要发展情况
• Vega Pharma Ltd.
• Teva Pharmaceuticals USA, Inc.
• Huvepharma
• Cipla Limited
• Medson Pharmaceuticals
• Medico Remedies Pvt. Ltd
• Zoetis
• AstraZeneca
• Kremoint Pharma Pvt.

第十四章：附录

Market Overview

The global aminoglycosides market reached US$ 1,636.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,202.2 million by 2030. The global aminoglycosides market is expected to exhibit a CAGR of 3.8% during the forecast period (2023-2030).

The global aminoglycosides market is a thriving sector in the pharmaceutical industry, focusing on the treatment of severe bacterial infections. Aminoglycosides are significant antibiotics that are widely utilized in hospitals, clinics, and research laboratories. Recent market trends reveal an increase in demand for combination medicines as well as a noticeable emphasis on developing novel formulations. Significant developments in the global aminoglycosides market include R&D initiatives, regulatory approvals, and a rising application in veterinary medicine.

The growing prevalence of bacterial infections, the increasing aging population, and high antibiotic usage are the factors driving the global aminoglycoside market. The growing geriatric population is increasing the demand for aminoglycoside drugs. According to WHO 2022 projection, the global population aged 60 and up is expected to grow dramatically. By 2030, one in every six individuals worldwide will be 60 or older, with the population in this age group estimated to reach 1.4 billion, up from 1 billion in 2020.

Market Dynamics

The Rising Prevalence of Tuberculosis is Propelling the Growth of the Global Aminoglycoside Market.

The rising incidence of tuberculosis is one of the main factors driving the significant rise of the global aminoglycoside market. Strong antibiotics like aminoglycosides are necessary for the efficient treatment of tuberculosis, a serious bacterial illness. The need for aminoglycosides is growing as a result of the rising prevalence of tuberculosis, particularly in developing nations.

For instance, according to the Centers for Disease Control and Prevention report of 2023, in 2022, there were 8,300 reported cases of tuberculosis (TB) in the United States, resulting in a rate of 2.5 cases per 100,000 people. This is a modest rise from the 7,874 cases reported in 2021. In 2022, the incidence of tuberculosis remained at 2.5 incidents per 100,000 people.

The Growing Demand for Aminoglycoside in Veterinary Medicine is Driving the Growth of the Global Aminoglycoside Market.

The use of aminoglycosides in veterinary medicine has been continuously expanding, offering market players a lucrative opportunity. In livestock, companion animals, and aquaculture, aminoglycosides are commonly used to treat bacterial infections. These aminoglycosides are administered in-feed and in-water form in poultry and pig industries.

For instance, Mycoplasma and Escherichia coli are the most frequent causes of respiratory infections in poultry that need to be treated with aminoglycosides. Animals can be treated with aminoglycosides for bacterial infections Escherichia coli, Proteus, Pseudomonas, Salmonella, Shigella, Serratia, and Enterobacter. Owing to these reasons, veterinary medicine usage in bacterial infection will drive the global aminoglycosides market over the forecast period.

The Development of Drug Resistance is Hampering the Growth of the Global Aminoglycoside Market.

Antibiotic resistance is the ability of bacteria to tolerate the effects of antibiotics, rendering them useless in treating bacterial infections. Prolonged and inappropriate usage of aminoglycosides has contributed to the development of bacterial strains resistant to these antibiotics, decreasing their efficiency.

For instance, Methicillin-resistant Staphylococcus aureus (MRSA) and bacteria producing extended-spectrum beta-lactamase (ESBL) are becoming resistant to aminoglycosides. Infected patients' aminoglycoside resistance rates, phenotypes, and mechanisms have all been reported. Antibiotic-resistant bacteria, such as MRSA and ESBL-producing bacteria, are becoming a rising public health threat.

COVID-19 Impact Analysis

The COVID-19 outbreak has had a substantial influence on the global aminoglycosides industry. The pandemic disrupted worldwide supply chains and reduced demand for goods and services in a variety of industries, including the aminoglycosides industry. One of the most significant effects of COVID-19 on the aminoglycosides market is the disruption of supply chains, which has resulted in a decline in aminoglycoside antibiotic production.

The pandemic has also increased antibiotic usage, as individuals are becoming more concerned about their health and taking adequate prescriptions to avoid infections and lengthier hospital stays. However, aminoglycosides may have particular benefits in the fight against COVID-19. According to a 2021 paper published by the National Library of Medicine, aminoglycosides have the potential to be SARS-CoV-2 antivirals. In vitro, inhibition of murine hepatitis virus (MHV) was demonstrated by the aminoglycosides hygromycin B (hygB) and neomycin. Others discovered hygB activity against bovine and feline coronaviruses.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine is expected to have a substantial influence on the global aminoglycoside market. Because of the incidence of infectious diseases in war zones, has led to higher pricing, supply chain interruptions, and increased demand for aminoglycosides. These factors are predicted to reduce market demand, raise prices, and disrupt the supply chain, making it difficult for patients to get essential aminoglycoside drugs.

Furthermore, the conflict's indirect effects, such as lower economic growth and lower demand for healthcare services, may contribute to the market's pessimistic view. While the full extent of the conflict's impact is unknown, it is clear that the global aminoglycosides industry will be severely impacted.

Segment Analysis

The global aminoglycosides market is segmented based on product type, route of administration, application, and region.

The Gentamicin Segment is expected to hold a Dominant Position for the Global Aminoglycoside Market over the Forecast Period.

The gentamicin segment accounted for the highest market share accounting for approximately 27.3% of the aminoglycoside market in 2022. Gentamicin is an antibiotic that is commonly used to treat severe bacterial infections in many regions of the body. It is the preferred treatment for serious infections, and its market expansion is being supported by expanded R&D.

A recent study conducted in 2022 and entitled "Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review" highlights the efficiency of a typical starting dose of 7 mg/kg based on total body weight in both adults and children older than one month, including critically ill patients. The likelihood of attaining the targeted treatment outcome is observed to be higher with this dosing technique. Thus, owing to the above factors, the market segment is expected to hold the largest market share for the global aminoglycoside market over the forecast period.

Geographical Analysis

North America holds a Dominant Position in the Global Aminoglycoside Market.

North America is estimated to hold around 36.9% of the total market share throughout the forecast period. The high disposable income, presence of major market players, an aging population, high prevalence of bacterial infections, and rising incidence of antibiotic resistance are some of the key factors expected to drive the aminoglycoside market in North America region over the forecast period.

The market for antibiotic formulations containing aminoglycosides is expanding significantly as a result of the involvement of several manufacturers in their creation. A significant milestone was reached by the U.S.-based company Padagis in March 2022 when the FDA gave the generic version of Tobradex ophthalmic suspension, which has an AB rating, the go-ahead. Tobramycin and dexamethasone make up this medication's active components.

Tobradex Ophthalmic Suspension is primarily used for the treatment of inflammatory, steroid-responsive ocular disorders where a corticosteroid is necessary, as well as when there is a risk of superficial bacterial ocular infection. Hence, owing to the above factors, the market is expected to drive over the forecast period

Competitive Landscape

The major global players in the market include: Pfizer Inc, Vega Pharma Ltd., Teva Pharmaceuticals USA, Inc., Huvepharma, Cipla Limited, Medson Pharmaceuticals. Medico Remedies Pvt. Ltd, Zoetis, AstraZeneca, and Kremoint Pharma Pvt. Ltd., among others.

Why Purchase the Report?

• To visualize the global aminoglycosides market segmentation based on the product type, route of administration, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of aminoglycosides market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global aminoglycoside market report would provide approximately 49 tables, 53 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Application
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Rising Prevalence of Tuberculosis is Propelling the Growth of the Global Aminoglycoside Market.
    • 4.1.1.2. The Growing Demand of Aminoglycoside as Veterinary Medicine is Driving the Growth of the Global Aminoglycoside Market
  • 4.1.2. Restraints
    • 4.1.2.1. The Development of Drug Resistance is Hampering the Growth of the Global Aminoglycoside Market.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Product Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.1.2. Market Attractiveness Index, By Product Type
• 8.2. Neomycin*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Tobramycin
• 8.4. Gentamicin
• 8.5. Amikacin
• 8.6. Paromomycin
• 8.7. Streptomycin
• 8.8. Kanamycin
• 8.9. Others

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Injectables*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Feed
• 9.4. Intra-mammary
• 9.5. Topical
• 9.6. Oral

10. By Application

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.1.2. Market Attractiveness Index, By Application
• 10.2. Veterinary*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Skin Infection
• 10.4. Respiratory diseases
• 10.5. UTI & Pelvic Diseases
• 10.6. Other Diseases

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.6.1. The U.S.
    • 11.2.6.2. Canada
    • 11.2.6.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.6.1. Germany
    • 11.3.6.2. The U.K.
    • 11.3.6.3. France
    • 11.3.6.4. Italy
    • 11.3.6.5. Spain
    • 11.3.6.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.6.1. Brazil
    • 11.4.6.2. Argentina
    • 11.4.6.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.6.1. China
    • 11.5.6.2. India
    • 11.5.6.3. Japan
    • 11.5.6.4. Australia
    • 11.5.6.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Product Benchmarking
• 12.3. Company Share Analysis
• 12.4. Key Developments and Strategies

13. Company Profiles

• 13.1. Pfizer Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Vega Pharma Ltd.
• 13.3. Teva Pharmaceuticals USA, Inc.
• 13.4. Huvepharma
• 13.5. Cipla Limited
• 13.6. Medson Pharmaceuticals
• 13.7. Medico Remedies Pvt. Ltd
• 13.8. Zoetis
• 13.9. AstraZeneca
• 13.10. Kremoint Pharma Pvt.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us